Novo Nordisk (NVO) is trading at $41.30, above its short- and medium-term moving averages, while BMO Capital Markets lifted its target to $44 and kept a Market Perform rating on November 5, 2026. T...
BMO Capital Markets raised Novo Nordisk (NVO) from $40 to $44 and kept a Market Perform rating, citing strong Wegovy pill performance and U.S. sales 17% above consensus, according to the November 5, 2026 report. That matters because it gives NVO stock a higher referenced upside level from a named analyst house, but the unchanged rating signals the firm is not turning overtly bullish.
For traders, the key takeaway is that the fundamental read-through is supportive, but not enough to erase the market’s need for confirmation from price and volume.
NVO is quoted at $41.30, up 1.03% on the day, after moving in a $40.20 to $41.58 24-hour range. The short- and medium-term trend structure is still positive: SMA 7 at $40.77, SMA 20 at $40.02, and SMA 50 at $39.09, with the faster averages stacked above the slower ones. That is a clean bullish alignment.
The catch is location. 41 . 8214 puts the stock near the upper band rather than in a deep breakout state. In plain terms, the trend is up, but the tape is not cheap.
Source link
